Cryptococcal meningitis is the second top killer of people living with HIV in South Africa. In the second of a two-part series on access to treatment for the condition, Catherine Tomlinson puts the Spotlight on the drug liposomal amphotericin B (part one looked at flucytosine).
After seemingly endless delays, a critically important drug for the treatment of cryptococcal meningitis was recently approved in South Africa. Yet, while the approval of flucytosine was a major step forward, much more still needs to be done to ensure wide availability of this life-saving medicine for the second leading killer of people living with HIV. Catherine Tomlinson unpacks the details.